Advancing Cardiac Prevention: James Min\u2019s Vision
\nFebruary 20, 2025<\/p>\n
Dr. James Min, a board-certified cardiologist and radiologist, has been a pioneering figure in cardiovascular imaging. He played a key role in establishing coronary computed tomography angiography (CCTA) as a diagnostic tool. He founded Cleerly, aiming to revolutionize preventive cardiology through AI-powered plaque analysis. In a recent American Heart Association (AHA) interview, Min discussed his vision, ongoing research, and the impact of CCTA on patient care.<\/p>\n
Min\u2019s research at Weill Cornell showed that soft plaque analysis via CCTA could improve coronary disease detection. However, manual analysis was labor-intensive. To make it widely accessible, he developed AI-driven automation, allowing CCTA to be used for early disease detection, similar to mammograms or colonoscopies.<\/p>\n
The TRANSFORM Trial: A Large-Scale Validation
\nIn 2024, Min\u2019s team launched the TRANSFORM trial, a randomized study with 7,500 patients across 100 sites, led by Dr. Deepak Bhatt. By November 2024, 1,000 patients had been enrolled. The goal is to prove that personalized CCTA-based evaluation leads to better outcomes than traditional risk assessment.<\/p>\n
Scaling Innovation Through AI and Policy
\nCleerly\u2019s technology is reshaping cardiology. The American Medical Association (AMA) recently approved a Category 1 CPT code for advanced plaque analysis, expanding insurance coverage. Additionally, Cleerly introduced Cleerly Ischemia, an AI tool for blood flow assessment, further enhancing risk stratification.<\/p>\n
A New Era of Personalized Cardiac Care
\nMin believes CCTA could transform preventive cardiology by tracking plaque progression a nd identifying high-risk patients. He emphasized in his AHA interview:
\n\u201cOur goal is to prove that personalized cardiovascular evaluation and treatment surpass traditional population-based approaches.\u201d<\/p>\n